Developer docs
API playgroundTry for free, no card

Search company profiles

FDA Educator

Full company profile

uuid000mp45

Namestring
FDA Educator
Websiteurl
fdaeducator.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

FDA Educator is a privately held, for-profit company headquartered in Los Angeles, United States, founded in 2016. According to its firmographic profile, the company operates an online training platform that delivers in-depth research and subject-matter information on FDA-related regulatory topics, targeting both business and technical audiences. The platform is positioned as a specialized education resource rather than a broader compliance software suite, suggesting a content-and-instructional model aimed at professionals seeking FDA regulatory literacy.

The company's underlying technology stack and product architecture are not documented in the available source data, and no products, integrations, AI modalities, or platform features are enumerated. The public website at fdaeducator.com currently resolves to a default Plesk hosting page with no substantive company content, branding, or organizational disclosures, which materially weakens any inference about active operations, current content offerings, or product maturity. No pricing models, customer segments, distribution channels, partnerships, management team, or compliance certifications are recorded.

From a business model perspective, the company self-identifies as an online training platform, implying some combination of course fees, subscriptions, or sponsored content as the likely revenue mechanics, but no pricing details, publicly disclosed rates, or customer counts are available to confirm the model. Headcount is reported at 1-10 employees, no funding rounds have been disclosed, and no parent company or subsidiaries are indicated. Given the absence of disclosed financials and the dormant public web presence, the company appears to be a small, likely bootstrapped niche education venture with no observable scale signals at present.

Short descriptiontext

FDA Educator is a Los Angeles-based online training platform, founded in 2016, that delivers in-depth research and subject-matter content on FDA regulatory topics to business and technical professionals, operating with a 1-10 person team.

Operating statusenum
Unknown
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
FDA regulatory training, online compliance education, regulatory affairs courses, life sciences training, pharmaceutical regulatory education
Industry2 codes
PRIMARYEDABALAU
Pharmaceuticals & Biotechnology
Education/Corporate Training & Professional Development/Industry-Specific Professional Training (e.g., Healthcare, Manufacturing, Construction)
SECONDARYEDAAAPAA
Healthcare & Life Sciences
Education/Adult & Continuing Education/Industry-Specific Training (Healthcare, Tech, etc.)
NAICS code1 code
  • Professional and Management Development Training611430
SIC code1 code
  • Services-Educational Services8200
Product category
Regulatory Compliance Training
Social media profiles1 record
Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

FDA Educator operates an online training platform that offers in-depth research and subject-matter information targeted at businesses and technical professionals. The company is described as a small, privately held training provider founded in 2016 and based in Los Angeles.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Peers8 records
1ComplianceOnline
TypeDirect peer
Description

ComplianceOnline is a B2B online training and webinar provider focused on FDA regulatory, GMP, validation, and life sciences compliance topics. It directly mirrors FDA Educator's stated offering of online regulatory training for technical and business audiences.

2GlobalCompliancePanel
TypeDirect peer
Description

GlobalCompliancePanel delivers seminars and online courses on FDA, cGMP, GAMP, and pharmaceutical/device compliance. It competes head-to-head for the same enterprise compliance-training buyer that FDA Educator targets.

3BioPharma Institute
TypeDirect peer
Description

BioPharma Institute provides online, self-paced regulatory and technical training for the pharmaceutical, biotech, and medical device industries, including FDA-focused modules. Its product format and target buyer closely match FDA Educator's described offering.

TypeBroad incumbent
Description

RAPS is the dominant professional membership organization for regulatory affairs, offering certified training, online courses, and RAC credentialing. It serves the same FDA-regulated buyer base as FDA Educator but at much greater scale and credibility.

TypeDirect peer
Description

NetZealous operates Compliance Trainings, a B2B platform hosting FDA, HIPAA, and life sciences compliance webinars and seminars. It directly competes for the same training budget that FDA Educator would target.

TypeDirect peer
Description

EduQuest specializes in FDA QSR/Quality System Regulation training and has historically served medical device and pharma companies. It is a focused, niche FDA educator closely comparable in positioning to FDA Educator.

TypeEmerging player
Description

MasterControl offers an integrated training/quality management suite that includes compliance training modules aimed at FDA-regulated manufacturers. It overlaps with FDA Educator on training content but bundles it into a broader QMS platform.

TypeDirect peer
Description

KnowledgeCity provides online compliance and workplace training libraries, including FDA-related modules. It serves a similar SMB and enterprise training buyer and competes on course catalog breadth and LMS delivery.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FDA Educator

Regulatory Compliance Trainingfdaeducator.com

FDA Educator is a Los Angeles-based online training platform, founded in 2016, that delivers in-depth research and subject-matter content on FDA regulatory topics to business and technical professionals, operating with a 1-10 person team.

What FDA Educator does

FDA Educator is a privately held, for-profit company headquartered in Los Angeles, United States, founded in 2016. According to its firmographic profile, the company operates an online training platform that delivers in-depth research and subject-matter information on FDA-related regulatory topics, targeting both business and technical audiences. The platform is positioned as a specialized education resource rather than a broader compliance software suite, suggesting a content-and-instructional model aimed at professionals seeking FDA regulatory literacy.

The company's underlying technology stack and product architecture are not documented in the available source data, and no products, integrations, AI modalities, or platform features are enumerated. The public website at fdaeducator.com currently resolves to a default Plesk hosting page with no substantive company content, branding, or organizational disclosures, which materially weakens any inference about active operations, current content offerings, or product maturity. No pricing models, customer segments, distribution channels, partnerships, management team, or compliance certifications are recorded.

From a business model perspective, the company self-identifies as an online training platform, implying some combination of course fees, subscriptions, or sponsored content as the likely revenue mechanics, but no pricing details, publicly disclosed rates, or customer counts are available to confirm the model. Headcount is reported at 1-10 employees, no funding rounds have been disclosed, and no parent company or subsidiaries are indicated. Given the absence of disclosed financials and the dormant public web presence, the company appears to be a small, likely bootstrapped niche education venture with no observable scale signals at present.

FDA Educator firmographics

Firmographics
Name
FDA Educator
Website
https://fdaeducator.com
Company type
Private
Founded year
2016
Operating status
Unknown
Headcount range
1–10 employees
Short description
FDA Educator is a Los Angeles-based online training platform, founded in 2016, that delivers in-depth research and subject-matter content on FDA regulatory topics to business and technical professionals, operating with a 1-10 person team.
Ownership category
akta.pro rank

FDA Educator industry classification

Industry
Product category
Regulatory Compliance Training
NAICS
Professional and Management Development Training (611430)
SIC
Services-Educational Services (8200)
akta.pro industry
PRIMARYEDABALAU
Pharmaceuticals & Biotechnology
Education/Corporate Training & Professional Development/Industry-Specific Professional Training (e.g., Healthcare, Manufacturing, Construction)
SECONDARYEDAAAPAA
Healthcare & Life Sciences
Education/Adult & Continuing Education/Industry-Specific Training (Healthcare, Tech, etc.)

Keywords

  • FDA regulatory training
  • Online compliance education
  • Regulatory affairs courses
  • Life sciences training
  • Pharmaceutical regulatory education

Where FDA Educator is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Markets served

FDA Educator business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

FDA Educator product offering

Product offering

Core offering

FDA Educator operates an online training platform that offers in-depth research and subject-matter information targeted at businesses and technical professionals. The company is described as a small, privately held training provider founded in 2016 and based in Los Angeles.

Differentiator

Problem solved

Functional benefit

Companies that use FDA Educator

Customer profile

Ideal customer profiles1 record

FDA Educator technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

FDA Educator partnerships and signals

Strategic signal

Recent moves1 record

FDA Educator competitors and assessment

Company assessment

Direct peers

  • ComplianceOnline: ComplianceOnline is a B2B online training and webinar provider focused on FDA regulatory, GMP, validation, and life sciences compliance topics. It directly mirrors FDA Educator's stated offering of online regulatory training for technical and business audiences.
  • GlobalCompliancePanel: GlobalCompliancePanel delivers seminars and online courses on FDA, cGMP, GAMP, and pharmaceutical/device compliance. It competes head-to-head for the same enterprise compliance-training buyer that FDA Educator targets.
  • BioPharma Institute: BioPharma Institute provides online, self-paced regulatory and technical training for the pharmaceutical, biotech, and medical device industries, including FDA-focused modules. Its product format and target buyer closely match FDA Educator's described offering.
  • NetZealous (Compliance Trainings): NetZealous operates Compliance Trainings, a B2B platform hosting FDA, HIPAA, and life sciences compliance webinars and seminars. It directly competes for the same training budget that FDA Educator would target.
  • EduQuest (FDA Training): EduQuest specializes in FDA QSR/Quality System Regulation training and has historically served medical device and pharma companies. It is a focused, niche FDA educator closely comparable in positioning to FDA Educator.
  • KnowledgeCity: KnowledgeCity provides online compliance and workplace training libraries, including FDA-related modules. It serves a similar SMB and enterprise training buyer and competes on course catalog breadth and LMS delivery.

Broad incumbents

  • Regulatory Affairs Professional Society (RAPS): RAPS is the dominant professional membership organization for regulatory affairs, offering certified training, online courses, and RAC credentialing. It serves the same FDA-regulated buyer base as FDA Educator but at much greater scale and credibility.

Emerging players

  • MasterControl Training: MasterControl offers an integrated training/quality management suite that includes compliance training modules aimed at FDA-regulated manufacturers. It overlaps with FDA Educator on training content but bundles it into a broader QMS platform.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks6 records

Key highlights4 records

Customer concentration

FDA Educator social profiles

Digital presence

FDA Educator financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FDA Educator leadership team

Management profile

Number of profiles

FDA Educator funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FDA Educator M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FDA Educator

What does FDA Educator do?

FDA Educator operates an online training platform that offers in-depth research and subject-matter information targeted at businesses and technical professionals. The company is described as a small, privately held training provider founded in 2016 and based in Los Angeles.

When was FDA Educator founded?

FDA Educator was founded in 2016. It employs 1 to 10 people.

Where is FDA Educator based?

FDA Educator is headquartered in Los Angeles, United States, in the North America region.

Who are FDA Educator's main competitors?

Direct peers on record are ComplianceOnline, GlobalCompliancePanel, BioPharma Institute, NetZealous (Compliance Trainings), EduQuest (FDA Training) and KnowledgeCity. Regulatory Affairs Professional Society (RAPS) is listed as a broad incumbent. MasterControl Training is listed as an emerging player.

Does FDA Educator have an API?

No public API is recorded for FDA Educator.

What industry is FDA Educator in?

FDA Educator's product category is Regulatory Compliance Training. Its primary akta.pro industry code is EDABALAU, Pharmaceuticals & Biotechnology, with a secondary code of EDAAAPAA, Healthcare & Life Sciences. Its NAICS code is 611430 and its SIC code is 8200.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageOS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary MetastaticOS Therapies announced that the U.S. FDA has granted a Type C Statistical Methods Meeting scheduled for mid-September 2026 to review 2.5-year overall survival data for its osteosarcoma therapy, OST-HER2. Concurrently, the U.K. MHRA granted a Scientific Advice Meeting to discuss statistical methods supporting the company's pending Conditional Marketing Authorisation Application. The company expects interim 3-year survival data in early September 2026 to facilitate decisions on regulatory designations and a potential Biologics License Application submission by year-end.Investing.comCingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.comCingulate Inc. reported a net loss of $5.9 million for the second quarter ended June 30, 2026, while announcing plans to resubmit its New Drug Application for the ADHD treatment CTx-1301 following a Complete Response Letter from the FDA. The company raised $31.0 million through equity offerings to extend its cash runway into mid-2027 and signed an exclusive services agreement with Prasco, LLC to establish commercial distribution infrastructure for the drug if approved.School of Public HealthFirst mRNA flu shot gets FDA approval, raising hopes for a more effective vaccineThe FDA has granted full approval for Moderna's mFlusiva, the first mRNA-based flu vaccine, for adults aged 50 to 64, with accelerated approval for those over 65. This decision follows a previous refusal by the agency and political scrutiny, marking a significant milestone for Moderna's mRNA platform and offering a potentially more effective alternative to traditional seasonal flu vaccines.CSP Daily NewsWhat retailers need to know about the FDA’s new tobacco enforcement guidanceThe FDA released new enforcement guidance in May that replaces previous discretion policies for unauthorized vapor and nicotine pouch products, stating it will generally not prioritize enforcement against manufacturers with accepted premarket applications. The agency plans to create a public list of these non-prioritized products to provide retailers with greater clarity on which items they can stock without immediate regulatory risk. This guidance distinguishes between pending applications and fully authorized products, noting that only a small fraction of the market has received formal approval.Ts2Agios Pharmaceuticals (NASDAQ:AGIO) pops as FDA review moves price above average targetAgios Pharmaceuticals shares rose 14.9% after the U.S. FDA accepted its supplemental New Drug Application for mitapivat to treat sickle cell disease, granting it Priority Review with a PDUFA target date of November 1. The stock traded at $42.95, exceeding analyst price targets as investors reacted to the potential approval of the first oral pyruvate kinase activator for this condition. Agios is scheduled to report second-quarter earnings on July 30, following a first quarter where mitapivat net revenue grew to $20.7 million.FortuneWhat Is NMN: Everything You Need to Know From ExpertsNMN (nicotinamide mononucleotide) is a naturally occurring compound that converts to NAD+, a coenzyme essential for cellular energy production and metabolism, with levels declining in middle age. The FDA restricted NMN supplement sales in 2022 over regulatory classification concerns but lifted the ban in 2025, allowing the supplement to return to market with clinical trials resuming. While research demonstrates that NMN increases NAD+ levels in the blood and tissues, experts caution that translating these findings into proven human health and anti-aging benefits requires more large-scale, long-term clinical studies.PolitiFactGenerally recognized as safe? The FDA may reconsider corn syrup, other processed food ingredientsThe FDA is considering re-evaluating the safety status of corn syrup and other processed food ingredients. The article discusses potential regulatory changes and the involvement of various political and advocacy groups.BioSpaceLung Cancer Trial to Proceed After FDA Releases Hold on Merck, Daiichi’s ADCThe FDA has lifted its partial clinical hold on Merck and Daiichi Sankyo's antibody-drug conjugate ifinatamab deruxtecan (I-DXd), allowing the Phase III IDeate-Lung02 trial for relapsed small cell lung cancer to resume in the US. The trial was originally placed on hold last month after regulators detected a higher-than-expected rate of deaths related to interstitial lung disease. The companies have since implemented additional safety mitigation strategies including stricter enrollment eligibility criteria, more frequent unblinded data reviews, and enhanced investigator training, though the trial remains paused in the EU pending further discussions with the European Medicines Agency.JD SupraFDA Drives Digital Health Forward With Pilot Program for Chronic Condition DevicesThe FDA announced the Technology-Enabled Meaningful Patient Outcomes for Digital Health Devices Pilot (TEMPO) on December 5, 2025, a new voluntary risk-based enforcement approach supporting digital health device use for chronic condition management under the CMMI ACCESS payment model. Under this program, selected manufacturers can request FDA not enforce certain requirements such as premarket authorization, in exchange for sharing real-world device data with the agency. The FDA expects to select up to 10 U.S.-based manufacturers in each of four clinical areas: early cardio-kidney-metabolic, cardio-kidney-metabolic, musculoskeletal, and behavioral health, with the goal of enabling earlier market entry and generating evidence to support future regulatory assessments.Investing.comFDA warns Target, Walmart for selling recalled baby formula By Investing.comThe FDA issued warning letters to Target, Walmart, Kroger, and Albertsons for continuing to sell recalled ByHeart infant formula linked to a botulism outbreak that hospitalized 51 babies. Despite ByHeart initiating a recall on November 8 and expanding it to all inventory on November 11, FDA investigators found the recalled products remained on shelves at multiple store locations across numerous states. The retailers have 15 working days to respond with specific steps to address the violations.